𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Augmentation of restless legs syndrome with long-term tramadol treatment

✍ Scribed by Roberto Vetrugno; Chiara La Morgia; Roberto D'Angelo; Daniela Loi; Federica Provini; Giuseppe Plazzi; Pasquale Montagna

Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
62 KB
Volume
22
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Restless legs syndrome (RLS) augmentation, defined as a kind of suppression of the circadian rhythm of the disease in which sensory and motor symptoms appear earlier during the day (and over previously unaffected body parts), with a progressive phase advance until, backwards, the symptoms may cover the entire day, has been described only after treatment with dopaminergic drugs. We report clinical and polysomnographic accounts of a patient developing RLS augmentation after long‐term treatment with tramadol, an opioid agonist with selectivity for μ‐receptor and added norepinephrine and serotonin reuptake inhibition properties. Polysomnographic measures showed an improvement of RLS and a disappearance of diurnal sensory and motor RLS symptoms after tramadol was stopped. Our case confirms a recent retrospective report of augmentation of RLS after treatment with tramadol, and begs the question whether augmentation is truly restricted to dopaminergic drugs. © 2006 Movement Disorder Society

📜 SIMILAR VOLUMES

One-year treatment with standard and sus
One-year treatment with standard and sustained-release levodopa: Appropriate long-term treatment of restless legs syndrome?
✍ Claudia Trenkwalder; Victor Collado Seidel; Jörg Kazenwadel; Thomas C. Wetter; W 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB

## Abstract To investigate the long‐term efficacy and safety of sustained‐release (SR) in combination with regular‐release (RR) levodopa/benserazide in the treatment of restless legs syndrome (RLS), an open‐label, prospective, extension study of a preceding double‐blind crossover trial was performe

Augmentation as a treatment complication
Augmentation as a treatment complication of restless legs syndrome: Concept and management
✍ Diego García-Borreguero; Richard P. Allen; Heike Benes; Christopher Earley; Sven 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 184 KB

Augmentation constitutes the main complication of long-term dopaminergic treatment in restless legs syndrome (RLS). Although this condition was first described in 1996, and is characterized by an overall increase in severity of RLS symptoms (including earlier onset of symptoms during the day, faster

Long-Term follow-up on restless legs syn
Long-Term follow-up on restless legs syndrome patients treated with opioids
✍ Arthur S. Walters; Juliane Winkelmann; Claudia Trenkwalder; June M. Fry; Vandana 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 41 KB

## Abstract The medical records of 493 patients with restless legs syndrome (RLS) from three major centers were studied to determine the number and outcome of patients who had been treated with opioids as a monotherapy. At one time or another 113 patients (51 men, 62 women; age range, 37–88 years)

Long-term course of restless legs syndro
Long-term course of restless legs syndrome in dialysis patients after kidney transplantation
✍ Juliane Winkelmann; Anette Stautner; Walter Samtleben; Claudia Trenkwalder 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 61 KB

## Abstract Restless legs syndrome (RLS) is a common cause of sleep disturbance and is frequently experienced by hemodialysis patients. Factors triggering the disease in uremia have not yet been identified. To our knowledge, the course of RLS symptoms after kidney transplantation has not been inves

Treatment of restless legs syndrome with
Treatment of restless legs syndrome with the dopamine agonist alpha-dihydroergocryptine
✍ Frithjof Tergau; Stephan Wischer; Christian Wolf; Walter Paulus 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 293 KB

## Abstract An open pilot study with the dopamine agonist α‐dihydroergocryptine (DHEC) was conducted in 16 patients with idiopathic restless legs syndrome (RLS) over a period of 5 weeks. Following a drug‐free interval of 1 week, the patients were treated with daily doses of 10 to 40 mg DHEC. As com

Treatment of restless leg syndrome with
Treatment of restless leg syndrome with pergolide—an open clinical trial
✍ Juliane Winkelmann; Thomas C. Wetter; Karen Stiasny; Wolfgang H. Oertel; Claudia 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 331 KB

## Abstract Dopaminergic treatment with levodopa (L‐dopa) has been proven as the treatment of first choice in patients with restless leg syndrome (RLS). Augmentation of symptoms and end‐of‐dose rebound phenomena under L‐dopa/decarboxylase inhibitor treatment present major problems in some patients.